Beyond Gastric Emptying: A “Toxic” Lesson About Gastroparesis

Pasricha, Pankaj J.
February 2008
American Journal of Gastroenterology;Feb2008, Vol. 103 Issue 2, p424
Academic Journal
The first published controlled trial of intrapyloric botulinum toxin for gastroparesis failed to demonstrate a significant effect of treatment on symptoms, despite an improvement in gastric emptying. In this editorial, I discuss the limitations and implications of this study, with particular emphasis on what the use of botulinum toxin can teach us about the pathophysiology of gastroparesis and other gastrointestinal smooth muscle disorders.


Related Articles

  • PHARMA: CLINIC ROUNDUP.  // BioWorld Today;2/6/2014, Vol. 25 Issue 25, p10 

    The article reports on results from pharmaceutical firm Ipsen SA of Paris, France in February 2014 of the international phase III clinical trial of Dysport Next Generation (DNG), an injectable form of botulinum toxin type A, in cervical dystonia.

  • Botulinum toxin and its clinical aspects: An overview. Mukherjee, Shatavisa // International Journal of Green Pharmacy (Medknow Publications & ;Jan-Mar2015, Vol. 9 Issue 1, p1 

    Botulinum toxin (BTX), a potent neurotoxin which is produced by the bacterium Clostridium botulinum, consists of eight distinct neurotoxin serotypes referred to as (BTX type-A [BTX-A], B, C, D, E, F, G, H) all of which inhibit acetylcholine release at the neuromuscular junction. BTX-A, by...

  • Botulinum toxins: Pharmacology and its current therapeutic evidence for use. Panicker, J. N.; Muthane, U. B. // Neurology India;Dec2003, Vol. 51 Issue 4, p455 

    Botulinum toxins are, as a group, among the most potent neuromuscular toxins known, yet they are clinically useful in the management of conditions associated with muscular and glandular over-activity. Botulinum toxins act by preventing release of acetylcholine into the neuromuscular junction....

  • NO NEED TO SWEAT EXCESSIVE PERSPIRATION.  // USA Today Magazine;Jul2012, Vol. 141 Issue 2806, p7 

    The article reports on cosmetic dermatologist Erin Welch's suggestion of undergoing botulinum toxin (Botox) injections to avoid excessive perspiration because Botox blocks the neurotransmitter acetylcholine which sends the signal to stimulate sweat glands.

  • Corrugator supercilii transection for headache emanating from the frontal region: a clinical evaluation of ten patients. Ru, J.; Schellekens, P.; Lohuis, P. // Journal of Neural Transmission;Nov2011, Vol. 118 Issue 11, p1571 

    Chronic daily headache (CDH) located in the frontal region is a common problem. We have previously described the positive results that were achieved with botulinum toxin (BTX) injections in the musculus corrugator supercilii (MCS) for this disorder. Nowadays, we offer transection of this muscle...

  • Diffuse Esophageal Spasm. Grübel, Claudia; Borovicka, Jan; Schwizer, Werner; Fox, Mark; Hebbard, Geoff // American Journal of Gastroenterology;Feb2008, Vol. 103 Issue 2, p450 

    The purpose of this article is to review the clinical features, pathophysiology, diagnosis, and management of patients with diffuse esophageal spasm (DES). The PubMed database was searched with a focus on recent publications, using keywords “DES,” plus...

  • ACQUIRED ENTROPION.  // Review of Optometry;4/17/2009 Supplement, p9A 

    The article offers information on the symptoms, pathophysiology and treatment of acquired entropion. Entropion is a condition of eyelid malpositioning. Symptoms associated with entropion include ocular irritation, foreign body sensation, tearing or epiphora and persistent red eye. The four...

  • Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. Hefter, Harald; Spiess, Constanze; Rosenthal, Dietmar // Journal of Neural Transmission;May2014, Vol. 121 Issue 5, p513 

    The objective of this study was to estimate the probability of development of partial secondary treatment failure (PSTF) in patients with cervical dystonia (CD) who had been treated over up to 9 years with repetitive intramuscular injections of botulinum neurotoxin type A (BoNT/A). The temporal...

  • First placebo-controlled trial of Botox for incontinence.  // Inside MS;Dec2005/Jan2006, Vol. 23 Issue 6, p34 

    The article reports on a clinical trial of botulinum toxin type A. A study was conducted to determine the effect of botulinum toxin on neurogenic overactive bladder, which is a kind of urinary incontinence associated with multiple sclerosis. Results showed that those who were injected with the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics